In the Hot Topics Debate session at the Society of Interventional Radiology’s annual scientific meeting in San Francisco, USA, co-ordinated by Daniel Sze, William T Kuo and John F Angle spoke for the motion “catheter-based lysis is superior to intravenous lysis and surgery for massive and submassive pulmonary embolism”. They took on the Scott O Trerotola and Suresh Vedantham who spoke against the motion and argued that there were no data to support catheter interventions for pulmonary embolism.
Renal Denervation is one of the hottest topics in medical devices at the moment and German outfit ReCor Medical has been in the fray with its announcement of CE marking for its Paradise™ system earlier this year (details here). Now the company has reported six-month follow-up data on eight patients who have been treated via renal denervation for their resistant hypertension with the company s unique ultrasound-based system.
Siemens Healthcare (SI) has announced that the Food and Drug Administration (FDA) has cleared the SOMATOM® Perspective – an advanced 128-slice computed tomography (CT) scanner engineered to drive efficiency and reduce costs.
To enable hospitals to keep pace with the latest technological advances and offer better patient care and improved workflow while containing costs, Toshiba America Medical Systems, Inc. announces the availability of VeloCT. This console upgrade includes new enhancements for patient safety, dose management and workflow for existing Aquilion™ 32, Aquilion 64 and Aquilion CX CT systems manufactured between 2006 and 2012.
A filter used to block clots from passing from the veins in the legs to the arteries of the lung does not improve mortality rates for most patients suffering a pulmonary embolism. However, if a patient is unstable - in shock or requires a ventilator - filters can save lives.
Ultrasonix Medical Corporation has received CE certification for its SonixGPS technology for Regional Anesthesia and Vascular Access, which will be immediately available in all countries that are part of the European Community. First approved for use in Canada, the SonixGPS technology has been used in hospitals in British Columbia and Ontario since October 2011. Clinical studies have proven the accuracy and clinical benefits of using the new technology for guidance procedures such as nerve blocks for regional anesthesia, and pain management and vascular access procedures which deliver medications into a patient’s bloodstream.
SIR-Spheres® microspheres are well-tolerated and effective internal radiotherapy for unresectable, heavily pre-treated colorectal cancer liver metastases, according to results from a new study of more than 600 patients presented today at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting. The data were presented by lead investigator Andrew Kennedy, M.D., FACRO, from Cancer Centers of North Carolina and North Carolina State University. SIR-Spheres microspheres are manufactured by Sirtex and are the only fully FDA-approved microsphere radiation therapy for the treatment of colorectal liver metastases.
One-third of imaging tests performed to evaluate patients for possible pulmonary embolism may be unnecessary, a prospective observational study found. Among patients who had a CT scan or other imaging study as part of a work-up for pulmonary embolism, 32% (95% CI 31 to 34) of the tests would have been classified as "avoidable" according to a measure endorsed by the National Quality Forum, reported Christopher Kabrhel, MD, of Harvard University in Boston, and colleagues.
A filter used to block clots from passing from the veins in the legs to the arteries of the lung does not improve mortality rates for most patients suffering a pulmonary embolism. However, if a patient is unstable – in shock or requires a ventilator – filters can save lives. Furthermore, for unstable patients with a pulmonary embolism, it is crucial they receive clot-dissolving medications known as thrombolytic therapy.
The percutaneous embolization of varicocele requires which selective catheterisation of the internal spermatic vein(s) followed by its (their) occlusion with either a sclerosant or solid embolic devices came in for discussion at the GEST 2012 US meeting.
An animal study using a porcine model has identified some of the sequelae of gastric artery embolization for systemic suppression of the hunger hormone, ghrelin. Ghrelin levels may be reduced by embolizing its production centres in the gastric fundus; however, incomplete fundal embolization and concerns for non-target embolization remain obstacles to the success of the procedure, say researchers.
ViewRay has received US FDA 510(k) premarket notification clearance for its MRI-guided radiation therapy system. The ViewRay system features a combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI) for the treatment of cancer. ViewRay s treatment planning and delivery software received 510(k) premarket notification clearance in 2011.
Cordis has announced the launch of the Powerflex Pro .035” percutaneous transluminal angioplasty (PTA) dilatation catheter in Europe for the treatment of peripheral vascular disease in the lower extremities.
Two new denervation systems were launched at EuroPCR (Paris, 15–18 May 2012). Covidien unveiled its OneShot system and St Jude Medical announced the launch of the EnligHTN system. Both systems are designed to treat patients with hypertension who are not responsive to traditional medical therapy.
AngioDynamics (Nasdaq:ANGO ), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced it has completed its acquisition of Navilyst Medical. Based on yesterday s closing price of $12.44 the transaction is valued at $355 million. The combination of the two companies is expected to double AngioDynamics share of the vascular access market, build critical mass in the peripheral vascular market and establish a strong operating platform for future growth.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos